Do analysts rate JMAC or PURR?

Hyperliquid Strategies has a consensus target price of $12.72, suggesting a potential upside of 57.97%. Given Hyperliquid Strategies' stronger consensus rating and higher possible upside, analysts clearly believe Hyperliquid Strategies is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Hyperliquid Strategies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, JMAC or PURR?

Maxpro Capital Acquisition has higher earnings, but lower revenue than Hyperliquid Strategies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Hyperliquid Strategies $1M 1,162.82 -$16.01M -$7.37 N/A

Is JMAC or PURR more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Hyperliquid Strategies N/A -56.04% -52.22%

Do analysts recommend JMAC or CGEM?

Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 81.51%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cullinan Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has higher valuation & earnings, JMAC or CGEM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is JMAC or CGEM more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Cullinan Therapeutics N/A -51.45% -47.64%

Do analysts rate JMAC or COLL?

Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 55.28%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.17

Which has preferable valuation and earnings, JMAC or COLL?

Collegium Pharmaceutical has higher revenue and earnings than Maxpro Capital Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Collegium Pharmaceutical $796.33M 1.51 $62.87M $2.04 18.15

Do analysts recommend JMAC or WVE?

WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 321.91%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 WAVE Life Sciences 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.87

Which has preferable valuation and earnings, JMAC or WVE?

Maxpro Capital Acquisition has higher earnings, but lower revenue than WAVE Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A WAVE Life Sciences $71.80M 16.78 -$204.38M -$1.06 N/A

Which has higher valuation and earnings, CRVS or JMAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is CRVS or JMAC more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -38.92% -35.75% Maxpro Capital Acquisition N/A N/A N/A

Maxpro Capital Acquisition (JMAC) Competitors

$19.56 -0.60 (-2.98%)

As of 07/2/2026

Compare

JMAC vs. PURR, CGEM, COLL, WVE, and CRVS

Should you buy Maxpro Capital Acquisition stock or one of its competitors? MarketBeat compares Maxpro Capital Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maxpro Capital Acquisition include Hyperliquid Strategies (PURR), Cullinan Therapeutics (CGEM), Collegium Pharmaceutical (COLL), WAVE Life Sciences (WVE), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

How does Maxpro Capital Acquisition compare to Hyperliquid Strategies?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

In the previous week, Hyperliquid Strategies had 3 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 3 mentions for Hyperliquid Strategies and 0 mentions for Maxpro Capital Acquisition. Hyperliquid Strategies' average media sentiment score of 0.53 beat Maxpro Capital Acquisition's score of 0.00 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Hyperliquid Strategies	Positive

Maxpro Capital Acquisition has higher earnings, but lower revenue than Hyperliquid Strategies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Hyperliquid Strategies	$1M	1,162.82	-$16.01M	-$7.37	N/A

Hyperliquid Strategies has a consensus target price of $12.72, suggesting a potential upside of 57.97%. Given Hyperliquid Strategies' stronger consensus rating and higher possible upside, analysts clearly believe Hyperliquid Strategies is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Maxpro Capital Acquisition's return on equity of 0.00% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Summary

Hyperliquid Strategies beats Maxpro Capital Acquisition on 7 of the 11 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Cullinan Therapeutics?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Cullinan Therapeutics'average media sentiment score.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Cullinan Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 81.51%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Maxpro Capital Acquisition's return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Summary

Maxpro Capital Acquisition and Cullinan Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Collegium Pharmaceutical?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 55.28%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17

Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 9.41% compared to Maxpro Capital Acquisition's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Maxpro Capital Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Collegium Pharmaceutical	9.41%	95.18%	16.39%

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Collegium Pharmaceutical and 0 mentions for Maxpro Capital Acquisition. Collegium Pharmaceutical's average media sentiment score of 1.50 beat Maxpro Capital Acquisition's score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Collegium Pharmaceutical	Very Positive

Collegium Pharmaceutical has higher revenue and earnings than Maxpro Capital Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Collegium Pharmaceutical	$796.33M	1.51	$62.87M	$2.04	18.15

Summary

Collegium Pharmaceutical beats Maxpro Capital Acquisition on 11 of the 13 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to WAVE Life Sciences?

Maxpro Capital Acquisition (NASDAQ:JMAC) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, suggesting that its share price is 229% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for WAVE Life Sciences and 0 mentions for Maxpro Capital Acquisition. WAVE Life Sciences' average media sentiment score of 1.14 beat Maxpro Capital Acquisition's score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
WAVE Life Sciences	Positive

Maxpro Capital Acquisition has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Maxpro Capital Acquisition's return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Maxpro Capital Acquisition has higher earnings, but lower revenue than WAVE Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
WAVE Life Sciences	$71.80M	16.78	-$204.38M	-$1.06	N/A

WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 321.91%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

WAVE Life Sciences beats Maxpro Capital Acquisition on 8 of the 12 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Corvus Pharmaceuticals' average media sentiment score of 0.00 equaled Maxpro Capital Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Corvus Pharmaceuticals	Neutral
Maxpro Capital Acquisition	Neutral

Maxpro Capital Acquisition's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Maxpro Capital Acquisition	N/A	N/A	N/A

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 118.87%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Corvus Pharmaceuticals is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Corvus Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Summary

Corvus Pharmaceuticals beats Maxpro Capital Acquisition on 5 of the 8 factors compared between the two stocks.

Get Maxpro Capital Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JMAC vs. The Competition

Export

Metric	Maxpro Capital Acquisition	Holding Offices Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$262.65M	$245.51M	$5.20B	$12.48B
Dividend Yield	N/A	3.45%	16.11%	6.52%
P/E Ratio	N/A	6.25	23.91	24.70
Price / Sales	N/A	0.14	216.83	99.49
Price / Cash	N/A	267.85	35.06	57.09
Price / Book	N/A	29.45	13.25	6.46
Net Income	N/A	-$9.10M	$113.80M	$337.01M
7 Day Performance	-5.96%	-0.33%	0.93%	1.69%
1 Month Performance	39.71%	-1.26%	1.08%	3.81%
1 Year Performance	218.57%	1.87%	10.03%	23.90%

Maxpro Capital Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JMAC Maxpro Capital Acquisition	N/A	$19.56 -3.0%	N/A	+198.2%	$262.65M	N/A	N/A	2,021	Gap Down
PURR Hyperliquid Strategies	2.6153 of 5 stars	$8.74 +9.0%	$9.25 +5.8%	N/A	$1.16B	$1M	N/A	N/A	News Coverage Analyst Forecast Short Interest Increase Gap Down
CGEM Cullinan Therapeutics	2.2682 of 5 stars	$18.40 -0.4%	$32.00 +73.9%	+125.7%	$1.14B	N/A	N/A	30
COLL Collegium Pharmaceutical	3.4356 of 5 stars	$36.59 +5.0%	$57.50 +57.1%	+21.9%	$1.13B	$780.57M	17.94	210	Positive News High Trading Volume
WVE WAVE Life Sciences	3.4327 of 5 stars	$5.83 +1.4%	$26.41 +353.0%	-10.2%	$1.11B	$42.73M	N/A	240	Positive News Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JMAC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maxpro Capital Acquisition (JMAC) Competitors

JMAC vs. PURR, CGEM, COLL, WVE, and CRVS

How does Maxpro Capital Acquisition compare to Hyperliquid Strategies?

Summary

How does Maxpro Capital Acquisition compare to Cullinan Therapeutics?

Summary

How does Maxpro Capital Acquisition compare to Collegium Pharmaceutical?

Summary

How does Maxpro Capital Acquisition compare to WAVE Life Sciences?

Summary

How does Maxpro Capital Acquisition compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC vs. The Competition

Maxpro Capital Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maxpro Capital Acquisition (JMAC) Competitors

JMAC vs. PURR, CGEM, COLL, WVE, and CRVS

How does Maxpro Capital Acquisition compare to Hyperliquid Strategies?

Does the media favor JMAC or PURR?

Which has higher valuation and earnings, JMAC or PURR?

Do analysts rate JMAC or PURR?

Do insiders & institutionals have more ownership in JMAC or PURR?

Is JMAC or PURR more profitable?

Which has more risk and volatility, JMAC or PURR?

Summary

How does Maxpro Capital Acquisition compare to Cullinan Therapeutics?

Does the media prefer JMAC or CGEM?

Which has higher valuation & earnings, JMAC or CGEM?

Do insiders and institutionals believe in JMAC or CGEM?

Do analysts recommend JMAC or CGEM?

Is JMAC or CGEM more profitable?

Which has more volatility and risk, JMAC or CGEM?

Summary

How does Maxpro Capital Acquisition compare to Collegium Pharmaceutical?

Do analysts rate JMAC or COLL?

Which has more volatility & risk, JMAC or COLL?

Is JMAC or COLL more profitable?

Do insiders and institutionals hold more shares of JMAC or COLL?

Does the media favor JMAC or COLL?

Which has preferable valuation and earnings, JMAC or COLL?

Summary

How does Maxpro Capital Acquisition compare to WAVE Life Sciences?

Which has more volatility and risk, JMAC or WVE?

Does the media refer more to JMAC or WVE?

Is JMAC or WVE more profitable?

Which has preferable valuation and earnings, JMAC or WVE?

Do analysts recommend JMAC or WVE?

Do institutionals and insiders hold more shares of JMAC or WVE?

Summary

How does Maxpro Capital Acquisition compare to Corvus Pharmaceuticals?

Which has higher valuation and earnings, CRVS or JMAC?

Does the media prefer CRVS or JMAC?

Is CRVS or JMAC more profitable?

Do insiders and institutionals believe in CRVS or JMAC?

Do analysts prefer CRVS or JMAC?

Which has more risk and volatility, CRVS or JMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC vs. The Competition

Maxpro Capital Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools